

QT Imaging inks exclusive distribution agreement with Gulf Medical for Saudi Arabia

26 August 2025 | News

Shipments of five scanners per quarter starting on Q1'26 for total revenue of approximately \$33 million over three years

QT Imaging Holdings, Inc. (QTI), a medical device company engaged in research, development, and commercialisation of innovative body imaging systems, has entered into an exclusive distribution agreement with Gulf Medical Co. (GMC) in Saudi Arabia.

The US FDA-cleared QTI Breast Acoustic CT™ scanner is the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionising radiation. The company also recently unveiled its ongoing strategic initiative to build the QTI Cloud Platform, designed to transform breast health through imaging intelligence.

Utilising a tiered Software as a Service (SaaS) delivery model, the QTI Cloud Platform will provide subscribers with access to a large and growing portfolio of AI-driven tools that automate findings classification and deliver consistent second-read decision support.

Under the terms of the Agreement, GMC will become the exclusive distributor of QTI Breast Acoustic CT™ scanners and user subscriptions to the QTI Cloud Platform in the Territory. The Agreement provides for minimum order quantities of five scanners per quarter, starting in the first quarter of 2026, through the end of 2028, for a total minimum of 60 scanners and revenue of more than \$33 million.

QTI breast imaging technology providing a solution for younger women is well suited as genetic predispositions, particularly BRCA1 and BRCA2 mutations, significantly contribute to the increased incidence of breast cancer in this region. Studies have reported a higher prevalence of BRCA mutations among Saudi Arabian women with breast cancer compared to other populations, suggesting a unique genetic susceptibility within this group. A large proportion of breast cancer cases in Saudi Arabia occur among women aged 40 to 59 years, underscoring the critical need for targeted awareness campaigns and screening initiatives to promote early detection and improve prognoses.